BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT04366622
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT04364464
US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 100
- Registration Number
- NCT04356339
- Locations
- 🇺🇸
myBETAapp, Whippany, New Jersey, United States
Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 493
- Registration Number
- NCT04356989
- Locations
- 🇨🇳
Many Locations, Multiple Locations, Taiwan
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 22
- Registration Number
- NCT04322253
- Locations
- 🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 18
- Registration Number
- NCT04320771
- Locations
- 🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
🇩🇪APEX GmbH, München, Bayern, Germany
Study to Learn About Relapse Prevention of Hypericumextract (a Drug Based on the Plant St. John Wort) in Outpatients Suffering From Moderate Depressive Episodes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 398
- Registration Number
- NCT04315597
Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 57
- Registration Number
- NCT04307186
- Locations
- 🇧🇬
UMHAT Sveti Georgi, Plovdiv, Bulgaria
🇧🇬University Multiprofile Hosp. for Active Treat. Sveti Ivan, Sofia, Bulgaria
🇯🇵National Hospital Organization Kanmon Medical Center, Shimonoseki, Yamaguchi, Japan
Study to Collect Information on How Well the Study Drug Naproxen Sodium Tablets Works Compared to Hydrocodone/Acetaminophen Tablets in Order to Relieve Pain in Participants Experiencing Moderate to Severe Pain After Having Their Wisdom Teeth Removed
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 221
- Registration Number
- NCT04307940
- Locations
- 🇺🇸
JBR Clinical Research, Salt Lake City, Utah, United States
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1601
- Registration Number
- NCT04304534
- Locations
- 🇺🇸
Maryland Cardiovascular Specialists, Baltimore, Maryland, United States
🇺🇸Logan Health Research, Kalispell, Montana, United States
🇳🇱Reinier de Graaf Gasthuis, Delft, Netherlands
© Copyright 2024. All Rights Reserved by MedPath